Alison Avallone, APRN
Family · New York, NYNPI 1134726540
Payments from drug & device makers
Across 102 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$377
- Novo Nordisk$351
- Lilly USA, LLC$168
- GSK$133
- AbbVie$130
- Idorsia Pharmaceuticals US Inc$105
- plus $635 from 15 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$1,83997%
- Education$342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $377 |
| Novo Nordisk | 23 | $351 |
| Lilly USA, LLC | 6 | $168 |
| GSK | 9 | $133 |
| AbbVie | 7 | $130 |
| Idorsia Pharmaceuticals US Inc | 7 | $105 |
| Abbott | 5 | $95 |
| Bayer | 5 | $94 |
| Boehringer Ingelheim | 4 | $61 |
| Phadia US Inc. | 2 | $53 |
| Pfizer | 3 | $48 |
| Millicent US Inc | 3 | $48 |
| Amgen | 3 | $46 |
| Exact Sciences | 2 | $41 |
| Medicure Pharma Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Boston Scientific | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,898 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 80 | $70,140 |
| JardianceEmpagliflozin | 36 | $40,486 |
| RybelsusSemaglutide | 17 | $35,893 |
| OzempicSemaglutide | 27 | $32,386 |
| MounjaroTirzepatide | 24 | $28,023 |
| EliquisApixaban | 24 | $22,696 |
| XareltoRivaroxaban | 15 | $14,378 |
| JanuviaSitagliptin Phosphate | 13 | $12,826 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,617 |
| Rosuvastatin Calcium | 104 | $2,207 |
| Atorvastatin Calcium | 150 | $1,717 |
| SynthroidLevothyroxine Sodium | 18 | $1,233 |
| Celecoxib | 25 | $1,092 |
| Metoprolol Succinate | 58 | $1,082 |
| Montelukast Sodium | 75 | $999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $377 | $70,14080 claims |
| Novo NordiskRybelsus, Ozempic | $351 | $68,27944 claims |
| Boehringer IngelheimJardiance | $61 | $40,48636 claims |
| Lilly USA, LLCMounjaro | $168 | $28,02324 claims |
| PfizerEliquis | $48 | $22,69624 claims |
| AbbVieSynthroid | $130 | $1,23318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.